FDA CBER OTP Convenes Town Hall on CMC Readiness Standards for Gene Therapy BLA Submissions

Sponsors advancing gene therapy programs toward licensure received direct regulatory guidance from FDA's Center for Biologics Evaluation and Research (CBER) on June 4, 2024, when the Office of Therapeutic Products convened a virtual town hall focused exclusively on chemistry, manufacturing, and controls requirements for biologics license applications. For CMC leads and regulatory affairs directors managing pre-BLA timelines, the session signals where CBER reviewers are finding packages incomplete.

The 90-minute event, hosted by OTP's Office of Gene Therapy CMC, addressed the data and documentation needed to support both pre-BLA meetings and original BLA submissions. Core areas of focus included the commercial manufacturing process, product comparability protocols, and stability data packages, three areas that consistently generate deficiency letters when sponsors underestimate the evidentiary standard expected at the BLA stage.

The regulatory framework underlying these expectations is well established. Under 21 CFR Part 601 and applicable ICH guidance, CMC submissions for gene therapy biologics must demonstrate a sponsor's commitment to manufacturing and testing controls that assure product safety, identity, quality, purity, and potency. What the town hall format provided was direct Q&A access to the reviewers who evaluate those commitments, offering sponsors a clearer read on where documentation gaps are most likely to trigger review holds.

Comparability data carries particular weight for programs that have modified their manufacturing process between clinical and commercial scale. CBER's position is that any process change affecting product quality attributes requires a structured comparability exercise, and the evidentiary bar for demonstrating equivalence rises sharply as a program approaches BLA submission. Stability data packages face similar scrutiny: real-time data at the proposed commercial storage condition must be sufficient to support the claimed shelf life, with accelerated and stress data serving a supporting rather than primary role.

The town hall is part of OTP's ongoing virtual engagement series, designed to provide regulatory clarity to product developers ahead of formal submission interactions. Transcripts and event materials from the June 4 session are available through CBER's website, and recordings from prior town halls in the series remain accessible for teams building out their CMC strategies.

Sponsors with pre-BLA meetings scheduled in the next two to three quarters should treat the published transcript as a preparatory reference, particularly for comparability and stability sections where reviewer expectations are most precisely articulated.

Source: FDA CBER via OTP Town Hall Series (FDA.gov), June 4, 2024. Event held 11:00 a.m. – 12:30 p.m. ET; transcript available as PDF (345.97 KB) on the CBER website.